Science

Aug 25, 2025, 12:37

Stephen V Liu: Chronic Kidney Disease Risk After Cisplatin Chemotherapy

Stephen V Liu, Director of Thoracic Oncology, Chief, Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Robert C. Grant et al. published in JAMA Oncology:

“Development of chronic kidney disease after cisplatin chemotherapy use in JAMA Oncology. In over 9000 patients, 13.6% of patients developed CKD. Estimated glomerular filtration rate decreased by a mean of 8.1 mL/min/1.73m2, and low baseline eGFR was the greatest predictor of CKD.”

Title: Predicting Chronic Kidney Disease After Cisplatin Treatment Using Population-Level Data

Authors: Robert C. Grant, Jiang Chen He, Ning Liu, Sho Podolsky, Faiyaz Notta, Marzyeh Ghassemi, Steven Gallinger, Andrea Knezevic, Sheron Latcha, Edgar Jaimes, Abhijat Kitchlu, Kelvin Chan

You can read the Full Article on JAMA Oncology.

Stephen V Liu: Chronic Kidney Disease Risk After Cisplatin Chemotherapy

More posts featuring Stephen V Liu.

Abhijat Kitchlu Andrea Knezevic cancer chronic kidney disease Cisplatin Edgar Jaimes Faiyaz Notta Jiang Chen He Kelvin Chan Marzyeh Ghassemi Ning Liu OncoDaily Oncology Robert C. Grant Sheron Latcha Sho Podolsky Stephen V Liu Steven Gallinger

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...